5-MeO-DMT work

1. Introduction

Version followed: the regulated clinical-development frame for 5-MeO-DMT (mebufotenin) as published by GH Research / Maastricht University for the investigational product GH001 (phase 1 in healthy volunteers, Reckweg et al. 2021; phase 1/2 in treatment-resistant depression, Reckweg et al. 2023; phase 2b results and FDA status per company release, January 2026), with the atai Beckley BPL-003 phase 2b (company release, July 2025) as a second programme; plus the naturalistic research literature from Johns Hopkins-affiliated investigators (Davis, Barsuglia, Lancelotta and colleagues) for the harm-reduction and integration role. This guide gives no doses, routes, schedules, sourcing or preparation details.

What it is. "5-MeO-DMT work" is not a single named psychotherapy. It is a cluster of practices around one fast-acting, short-lasting tryptamine: (1) industry-sponsored clinical trials of investigational products in treatment-resistant depression (TRD), and (2) unregulated retreat, ceremonial and private use, which naturalistic surveys have studied. [source: Reckweg et al. 2021; Reckweg et al. 2023; Davis et al. 2018]

How change is thought to happen. In the GH001 programme the active ingredient is treated as the drug effect itself. The authors state that the short, ineffable experience lets the product be given without formal preparation sessions, guided sessions or integration, and that no specific psychotherapeutic interventions were used. Rapid remission, present by the day after treatment, is the proposed route of benefit, not a psychotherapy process. [source: Reckweg et al. 2023] Naturalistic researchers relate reported benefits to the intensity of mystical-type or non-dual experiences. [source: Barsuglia et al. 2018; Davis et al. 2018] Dourron et al. (2023) offer a speculative alternative: that some effects, including the frequently reported "reactivations", resemble epileptiform activity. [source: Dourron et al. 2023 abstract] [uncertain: mechanism unresolved]

What this means for a psychotherapist. Unlike psilocybin or MDMA protocols, no published 5-MeO-DMT protocol includes a manualised psychotherapy. In practice your work is: (a) assessment, education and referral for clients interested in trials; (b) if you are on a trial team, carrying out the support, observation and follow-up roles the protocol assigns; (c) for clients who use 5-MeO-DMT outside clinics, harm reduction and integration support, never facilitation. Most procedures in section 4 are therefore marked [synthesis] where the sources describe only the frame. [synthesis]

Legal and regulatory status (as of the sources' dates). USA: Schedule I since January 2011; GH001 is an investigational drug, and the FDA lifted the clinical hold on its IND in January 2026, with a global phase 3 planned for 2026 [source: Erowid law page; GH Research release, 5 Jan 2026]. UK: Class A / Schedule 1. Germany: highest control level since 1999. Sweden, Denmark (medical/scientific use only), Finland, Greece, Russia, China, Japan and New Zealand: controlled. Netherlands: not on the Opium Act lists as of August 2023 (which is how the Maastricht trials ran under research approval). Canada and Belgium: reported as not specifically controlled, unconfirmed. [source: Erowid law page, a secondary compilation] [uncertain: verify locally; laws change, and analogue laws may apply]. No 5-MeO-DMT product is approved for clinical use anywhere in the sources reviewed. [source: GH Research 2026; atai 2025]

2. Framework

5-MeO-DMT has no psychotherapy phase model. The stages below are the trial pathway as published for GH001, with the clinician's parallel tasks added and marked.

Stage A. Pre-screen and referral. Goal: identify possible candidates and rule out obvious exclusions. In the GH001 phase 1/2, this was a telephone suitability screen after recruitment through media, agencies and clinics. [source: Reckweg et al. 2023] Clinician task: discuss trial participation, gather history, refer to the trial site, not to unregulated providers. [synthesis]

Stage B. Medical and psychiatric screening. Goal: confirm the diagnosis and safety. The GH001 TRD trial used a structured diagnostic interview (MINI), the MGH SAFER criteria for a valid current episode, depression severity thresholds on the MADRS and a global severity rating, and confirmed inadequate response to at least two adequate treatments in the current episode (one could be psychotherapy). Exclusions, as published: psychotic disorders or psychotic depression; bipolar disorder, including in immediate family; OCD; autism spectrum disorder; borderline personality disorder; clinically significant intellectual disability; suicide risk; other comorbidity judged unsuitable; significant medical contraindications; prior significant adverse reaction to, or non-response to, a psychedelic or dissociative drug. Healthy-volunteer screening included medical examination and blood and urine tests. [source: Reckweg et al. 2021; Reckweg et al. 2023] Moving on: all criteria met, plus written informed consent.

Stage C. Medication taper and washout. Goal: remove interacting psychoactive medication. Participants on antidepressants or other psychoactive drugs went through a taper and washout before entry. This is managed by the trial physicians. [source: Reckweg et al. 2023] Clinician task: increase psychological contact during the taper, watch for relapse and suicidality, and liaise with the prescriber. [synthesis]

Stage D. Preparation. In GH001, preparation was "standard medical care": informed consent, a comfortable dosing environment, and medical and psychological support available throughout. Participants were told they would receive an active tryptamine psychedelic and were given information about expected effects, duration and possible adverse events. The identity of the compound and dose was withheld until the study ended, to limit expectancy effects. [source: Reckweg et al. 2021; 2023] No separate preparation sessions were described. Moving on: consent confirmed, washout complete, still eligible on the dosing day (in TRD, symptoms had not improved by more than a set margin since screening). [source: Reckweg et al. 2023]

Stage E. Dosing day in clinic. Goal: a safe acute experience. Medical staff hold responsibility for monitoring, including continuous remote vital-sign observation and timed checks that are not taken at the peak so as not to disrupt it. Dosing decisions are made by the physicians under the protocol and required participant consent. An independent Study Safety Group reviewed the data. [source: Reckweg et al. 2021; 2023] The acute experience lasts minutes, not hours; in the GH001 phase 2b, 99% of patients were ready for discharge within one hour [source: GH Research 2026]; in BPL-003, most were ready at the 90-minute check and on average within two hours [source: atai 2025]. Moving on: formal discharge-readiness assessment by clinical staff.

Stage F. Follow-up. GH001: phone contact the next day and a clinic visit at about day 7, with mood, cognition and safety ratings (suicidality, dissociation, brief psychiatric rating) by remote blinded raters. [source: Reckweg et al. 2021; 2023] BPL-003: ratings on days 2, 8, 29 and 57. [source: atai 2025] No integration sessions were described in either programme. [source: Reckweg et al. 2023; atai 2025 does not mention psychotherapy]

Stage G (outside trials). Harm reduction and integration. For clients who have used or plan to use 5-MeO-DMT in unregulated settings: assessment, risk education in general terms, safety planning, integration of the experience, monitoring for reactivations or lasting difficulties, and referral. Session count: no source; a reasonable frame is 1 to 3 sessions of assessment and education before, and 2 to 6 sessions of integration after, adjusted to need, in ordinary 50-minute individual psychotherapy. [synthesis]

3. Guiding principles

Harm reduction, never facilitation. Practical meaning: you may assess, educate in general terms and support, but you do not recommend providers, obtain substances, attend or supervise use outside a licensed trial. [synthesis]
Respect the protocol you work in. Practical meaning: the GH001 trials gave no specific psychotherapy; if you are on a trial team, do not add techniques the protocol does not allow, because that changes the study. [source: Reckweg et al. 2023; synthesis]
Medical decisions belong to medical staff. Practical meaning: medication tapering, dosing decisions, vital-sign monitoring and discharge are physician tasks; you report observations. [source: Reckweg et al. 2021; 2023]
Screening exclusions are safety rules, not hurdles. Practical meaning: a personal or immediate family history of bipolar disorder or psychosis, current suicide risk, borderline personality disorder and the other published exclusions rule out trial entry; do not coach clients around them. [source: Reckweg et al. 2023]
Informed consent must cover intensity and uncertainty. Practical meaning: explain that the experience can be overwhelming in its brief intensity, that blinding may apply, and that the evidence base is small and short-term. [source: Reckweg et al. 2021; 2023; synthesis]
Experience intensity is not the goal. Practical meaning: in naturalistic use, mystical intensity correlated with reported benefit, but associations are not causal; do not encourage clients to seek the strongest experience. [source: Barsuglia et al. 2018; Davis et al. 2018; Lancelotta & Davis 2020]
Reactivations are expected and usually benign, but must be asked about. Practical meaning: always ask about sudden re-experiencing after use; most are rated neutral or positive, but who will find them distressing is not known. [source: Ortiz Bernal et al. 2022]
Meaning belongs to the client. Practical meaning: "non-dual awareness", "death and rebirth" or "oneness" are the client's or a tradition's interpretation; reflect them without endorsing or debunking them. [synthesis]
Respect ceremonial and cultural authority. Practical meaning: ceremonial contexts are governed by the communities that hold them; you neither run nor describe ceremony, and you treat what clients report as their experience. [synthesis]
Unregulated product is an unknown. Practical meaning: potency and identity varied even in a medically staffed retreat; tell clients plainly that what is sold outside regulated trials cannot be assumed to be what it is said to be. [source: Barsuglia et al. 2018 limitations; synthesis]
Humility about the evidence. Practical meaning: trial samples were small, selected and followed briefly; do not promise remission. [source: Reckweg et al. 2023; atai 2025]

4. Intervention inventory

No published 5-MeO-DMT programme specifies psychotherapeutic techniques: GH001 used none, and the BPL-003 release does not mention any. [source: Reckweg et al. 2023; atai 2025] The items below are therefore the frame tasks the trial papers describe (A1 to A6) and harm-reduction and integration procedures for clients outside trials (B1 to B9). Step-by-step content is [synthesis] unless a source tag says otherwise. All example language is illustrative.

A1. Initial assessment of a client asking about 5-MeO-DMT

Purpose / when: First contact whenever a client mentions trials, retreats or past use. It sets the risk picture and the route (trial referral, harm reduction, integration, or none). [synthesis]
Steps: (1) Ask what they have heard and why it appeals to them now. (2) Take a psychiatric history mapped onto the published exclusions: psychosis, bipolar disorder (including first-degree relatives), OCD, autism, borderline personality disorder, intellectual disability, current suicidality. [source: Reckweg et al. 2023] (3) Ask about past psychedelic or dissociative experiences, especially severe adverse reactions or non-response, which the GH001 trial also excluded. [source: Reckweg et al. 2023] (4) List current medications and other substances, and the prescriber's name. (5) Ask about cardiovascular and other medical conditions, and about any seizure history, given the hypothesised epileptiform component [source: Dourron et al. 2023; uncertain whether this is a real risk]. (6) Summarise back and agree a next step. [synthesis]
Example language (illustrative): "Before we talk about whether this fits you, I'd like to understand your history, including your family's, because some conditions make these substances riskier."
Watch for: urgency driven by despair (screen for suicide risk at once); minimising family history; pressure to stop medication quickly. Working: the client gives a full history and can hear safety information without dismissing it.

A2. Trial pre-screen and referral

Purpose / when: The client has TRD and wants a regulated route. [synthesis]
Steps: (1) Check rough fit with published inclusions: major depressive episode without psychotic features, inadequate response to at least two adequate treatments in the current episode (one could be a psychotherapy). [source: Reckweg et al. 2023] (2) Explain that trials screen with structured interviews and rating scales and may ask for a supervised medication washout. [source: Reckweg et al. 2023] (3) Help the client find registered trials (trial registries, the sponsor's site), not commercial retreats. (4) With consent, send a referral summary. (5) Prepare them for the possibility of exclusion or placebo/active-control allocation. [source: atai 2025 for active-control design; synthesis]
Example language (illustrative): "A trial is the only route I can help you with. They'll do their own careful screening, and they may decide it's not right for you. That's a safety decision, not a judgement of you."
Watch for: distress after exclusion; requests to omit history from the screening. Working: the client engages with the site and keeps you informed.

A3. Informed-consent and expectation conversation

Purpose / when: Before trial entry (to support, not replace, the site's consent) or whenever a client is considering use. [synthesis]
Steps: (1) Describe the published profile in plain terms: a very brief but intense experience lasting minutes, followed by quick return to baseline. [source: GH Research 2026; atai 2025] (2) List adverse effects reported in trials: headache, nausea, anxiety, sensory disturbances, flashback-like effects, feeling hot, confusion, sleep problems and unusual dreams, short-lived blood-pressure or heart-rate rises, mostly mild to moderate and resolving on their own. [source: Reckweg et al. 2021; 2023; atai 2025] (3) Explain that the experience may be hard to put into words, and may include a sense of losing the self. [source: Reckweg et al. 2023 describes it as "ineffable"; Barsuglia et al. 2018] (4) Explain blinding where it applies: participants were not told the compound or dose. [source: Reckweg et al. 2021] (5) Say plainly that long-term data are limited. (6) Check understanding with teach-back. [synthesis]
Example language (illustrative): "People describe it as very short and very strong, sometimes as if their sense of self disappears for a while. Most side effects in trials were mild, but a few people felt anxious or had flashback-like moments afterwards."
Watch for: idealised expectations ("this will fix everything"); fear of losing control. Working: the client can describe both possible benefits and risks in their own words.

A4. Supporting the client through a medication taper

Purpose / when: A trial site has asked for a supervised washout. The taper is medical; your role is psychological. [source: Reckweg et al. 2023; synthesis]
Steps: (1) Agree contact frequency during the taper. (2) Make a relapse and crisis plan with warning signs, contacts and coping steps. (3) Rate mood and suicide risk at each contact with your usual instruments. (4) Report a deterioration to the prescriber and trial team the same day. (5) Support the client if the taper is stopped for safety. [synthesis]
Example language (illustrative): "Coming off medication can bring symptoms back. If that happens, we'll tell the trial doctor straight away. Stopping the taper is always an option."
Watch for: suicidal ideation, withdrawal effects, the client tapering on their own outside medical supervision. Working: stable or monitored mood and no unsupervised changes.

A5. Psychological presence on the dosing day (trial staff only)

Purpose / when: Only if the protocol gives you a role. GH001 provided a comfortable environment and "availability of medical and psychological support" but no guided session. [source: Reckweg et al. 2023] The sources describe no music, eye shades or touch policy; the Barsuglia retreat had a physician and a facilitator present. [source: Barsuglia et al. 2018] [uncertain: staffing and conduct details not published in the sources]
Steps: (1) Learn the protocol's script, boundaries and touch policy before the day; if it has none, use no touch beyond what safety requires and what was agreed beforehand. [synthesis] (2) Before dosing, briefly remind the participant of what was agreed (they can signal distress; staff stay with them). (3) During the experience, stay present and quiet; physicians handle monitoring, and vital-sign checks are timed to avoid the peak. [source: Reckweg et al. 2021] (4) If the participant becomes distressed, use brief, calm orienting statements; escalate to the physician for any physical concern. (5) Afterwards, allow quiet time before asking questions; let the staff responsible run the discharge-readiness check. [source: GH Research 2026; synthesis]
Example language (illustrative): "You're safe. We're here with you. This will pass soon." Afterwards: "Take your time. There's no need to explain anything yet."
Watch for: panic, agitation, attempts to get up, nausea; any physical symptom goes to medical staff. Working: the participant returns to baseline and feels supported, not steered.

A6. Post-session check and early follow-up

Purpose / when: The day-1 and day-7 contacts in GH001 are protocol assessments. [source: Reckweg et al. 2021; 2023] A treating therapist outside the trial team can offer a session within the first week. [synthesis]
Steps: (1) Ask an open question about how the person is now. (2) Screen for suicidality, dissociation, sleep disturbance, flashback-like episodes and anxiety, which match the scales and adverse events in the trial papers. [source: Reckweg et al. 2023] (3) Ask whether anything is worrying them about the experience. (4) Report adverse events to the trial team if the client consents, or as the protocol requires. (5) Plan integration (B5 onwards) if wanted. [synthesis]
Example language (illustrative): "Since the session, have you had any moments when it felt like the effects were coming back?"
Watch for: early worsening, sudden elation or sleeplessness (possible hypomania), suicidal thoughts. Working: stable and oriented, and the person can talk about the experience.

B1. Harm-reduction assessment for planned use outside a trial

Purpose / when: A client tells you they intend to use 5-MeO-DMT at a retreat, ceremony or at home. Most respondents in the largest survey used it in private homes, and 68% said they did so for spiritual exploration. [source: Davis et al. 2018] Goal: keep the alliance and reduce risk without endorsing use. [synthesis]
Steps: (1) Thank them for telling you; state your role (you won't help them obtain it or take part, but you will help them think about safety). (2) Explore motives and what they hope will change. (3) Repeat the A1 risk history. (4) Explore alternatives, including trials and evidence-based treatments. (5) If they are still decided, go on to B2 and B3. (6) Document the conversation and your advice. [synthesis]
Example language (illustrative): "I can't help arrange this or be involved, and I'd like you to know my concerns. I'd rather you hear them from me than go in without them."
Watch for: the person concealing plans after feeling judged; a crisis motive ("it's my last hope"), which needs suicide-risk assessment first. Working: they stay open with you and take in the risk information.

B2. Risk education in general terms

Purpose / when: After B1, or with anyone who has used before and may use again. [synthesis]
Steps: (1) Psychiatric vulnerability: the trials excluded people with psychotic or bipolar disorders (or a family history of them), suicide risk and several other conditions, because these are where the risks are greatest. [source: Reckweg et al. 2023] (2) Medical: trials screened with examination, ECG and blood tests [source: Reckweg et al. 2021; Barsuglia et al. 2018]; advise a medical review with their own doctor. (3) Interactions: explain in general terms that combining it with other psychoactive substances or with many prescribed medications, especially those acting on serotonin, can be dangerous, and that a published fatality involved a preparation combining 5-MeO-DMT with other substances. [source: Davis et al. 2018] Give no combination or timing advice; refer medication questions to a doctor or pharmacist. (4) Unknown product: outside trials, identity and strength cannot be assumed; even in a medically staffed retreat, potency was thought to vary. [source: Barsuglia et al. 2018] (5) Psychological: challenging experiences such as fear or anxiety were reported by about 37% of survey respondents, mostly mild; about 4% reported psychiatric worsening; reactivations are common. [source: Davis et al. 2018; Ortiz Bernal et al. 2022] (6) Legal: it is a controlled drug in most of the jurisdictions listed in section 1. [source: Erowid law page] (7) Explain what regulated trials have (screening, physician monitoring, a safety review board, follow-up) so the client can see what an unregulated setting lacks. [source: Reckweg et al. 2021; 2023; synthesis]
Example language (illustrative): "In the trials, people with a family history of bipolar disorder weren't allowed to take part, because the risks are higher. That applies to you too, wherever you'd be."
Watch for: the client hearing education as approval. Say clearly that you are not recommending use. Working: they can repeat back the key risks for their own case.

B3. Safety and aftercare planning

Purpose / when: The client has decided to go ahead despite your advice, or has just used. [synthesis]
Steps: (1) Agree a written crisis plan: warning signs, who to contact, emergency numbers. (2) Encourage a trusted, sober person to be available afterwards and no driving or risky tasks the same day (the trials ran formal discharge-readiness checks before people left). [source: GH Research 2026; atai 2025; synthesis] (3) Plan time off and low demands afterwards. (4) Book a follow-up session within the week. (5) Agree that they will seek urgent medical help for chest pain, severe headache, fainting, seizure-like events or confusion that does not clear. [synthesis]
Example language (illustrative): "Let's write down what you'll do if you feel unsafe afterwards, and book a session for the week after."
Watch for: no available support person; plans to use alone. Working: a concrete plan and a booked follow-up.

B4. Medication and prescriber liaison

Purpose / when: The client is on psychiatric or other medication and is considering stopping it to use 5-MeO-DMT outside a trial. [synthesis]
Steps: (1) Advise clearly against stopping or changing medication without the prescriber. (2) With consent, contact the prescriber. (3) Watch for relapse if they have stopped. (4) Note that in trials, washout was done under medical supervision as part of screening. [source: Reckweg et al. 2023; synthesis]
Example language (illustrative): "Stopping your antidepressant suddenly carries its own risks. That's a conversation for you and your doctor, and I'm happy to help set it up."
Watch for: abrupt discontinuation, withdrawal, relapse. Working: medication decisions go through the prescriber.

B5. Integration: telling the story of the experience

Purpose / when: In the first integration session after any use, in or outside a trial. Neither trial programme offered integration; this is clinical support around them. [source: Reckweg et al. 2023; synthesis]
Steps: (1) Invite an uninterrupted account: before, during, after. (2) Accept fragments and gaps; the experience is often described as beyond words. [source: Reckweg et al. 2023] (3) Use open questions about bodily sensations, emotions and images. (4) Reflect back without interpreting. (5) Ask what felt important and what felt frightening. (6) Write down key phrases the client used, to return to later. [synthesis]
Example language (illustrative): "Start wherever you like. If there aren't words for parts of it, we can just notice that."
Watch for: shame at being unable to describe it; re-traumatisation when recounting fear. Slow down and use grounding. Working: the client feels heard and less confused.

B6. Working with ego dissolution and non-dual experiences

Purpose / when: The client reports loss of self, unity, "dying" or contact with something they call divine. Mystical-type experiences were common in naturalistic samples. [source: Barsuglia et al. 2018; Davis et al. 2018] A "non-substance-induced non-dual awareness" experience was associated with neutral or positive reactivations. [source: Ortiz Bernal et al. 2022]
Steps: (1) Ask what the experience meant to them, in their own frame (religious, secular, ambivalent). (2) Reflect the meaning without endorsing or arguing with its metaphysics. (3) Explore what changed in how they see themselves, others or death. (4) If there is a faith tradition involved, ask whether they want to talk with someone from it. (5) Separate the felt certainty from decisions; agree to wait before making big life changes. [synthesis]
Example language (illustrative): "It sounds like, for a moment, there was no 'you' separate from everything else. What has stayed with you from that?"
Watch for: grandiosity, special-mission beliefs, religious preoccupation with poor sleep (consider hypomania or psychosis and refer urgently); existential terror or derealisation that persists. Working: the experience is held as meaningful but is not driving risky decisions.

B7. Assessing and responding to reactivations

Purpose / when: At every follow-up. Reactivations, the sudden re-experiencing of effects, are frequently reported after 5-MeO-DMT, more than with typical psychedelics, and more often by women, those older at first use, more educated people and those who used it in structured group settings. Most are rated neutral or positive. [source: Ortiz Bernal et al. 2022; Dourron et al. 2023] "Flashback" also appears among adverse events in the trials. [source: Reckweg et al. 2021; 2023]
Steps: (1) Ask directly (frequency, triggers, duration, content, distress, function). (2) Normalise without dismissing. (3) For distressing episodes, teach grounding (orientation to place and time, slow breathing, sensory anchoring) and a plan for when one happens somewhere unsafe (sit down, stop driving). (4) Track them over time. (5) If episodes are frequent, involve loss of awareness, unusual movements or confusion, refer for medical and neurological assessment, given the hypothesised link to epileptiform activity. [source: Dourron et al. 2023; uncertain] (6) If perceptual changes persist between episodes, refer for psychiatric assessment. [synthesis]
Example language (illustrative): "Some people find that the effects briefly come back days or weeks later. Has anything like that happened to you? How did it feel?"
Watch for: fear of "going mad", avoidance of daily life, episodes while driving. Working: episodes become less frequent or less distressing and the client feels able to manage them.

B8. From insight to change

Purpose / when: Once the experience has been told and processed. In naturalistic surveys, many respondents reported improvement in depression, anxiety, PTSD or substance problems, but these are self-reports and associations. [source: Davis et al. 2018] [synthesis for method]
Steps: (1) Ask what the client wants to do differently. (2) Turn each aim into one small, concrete step. (3) Link it to your existing therapy (CBT, ACT, psychodynamic or other) rather than building a new one around the drug experience. (4) Review progress weekly. (5) Revisit the original treatment plan; continue evidence-based care. [synthesis]
Example language (illustrative): "You said you felt you didn't have to carry everything alone. What's one way to act on that this week?"
Watch for: waiting for the experience to do the work; wanting repeat use to recapture it. Working: concrete behaviour changes the client can name.

B9. Monitoring for lasting difficulties and referral

Purpose / when: For weeks to months after use. A minority of survey respondents reported psychiatric or medical worsening. [source: Davis et al. 2018]
Steps: (1) Use your standard measures for depression, anxiety, dissociation and suicide risk at agreed intervals. (2) Ask about sleep, appetite, perception and mood elevation. (3) Refer urgently for psychosis, mania, suicidality or neurological symptoms. (4) Refer to a psychiatrist for persistent perceptual changes or derealisation. (5) In a trial, tell the team (with consent) so adverse events can be recorded. [source: Reckweg et al. 2021 for adverse-event recording; synthesis]
Example language (illustrative): "I'd like to keep checking in on a few things for the next couple of months, just to be sure nothing has stayed with you that we should look at."
Watch for: delayed onset of symptoms. Working: stable or improving scores.

B10. Supporting clients after a harmful retreat or ceremony

Purpose / when: A client describes being pressured, left unsupervised, physically harmed, exploited or abused in an unregulated setting. The sources document no specific cases. [uncertain] [synthesis]
Steps: (1) Ensure current safety and medical needs. (2) Listen without blaming them for having gone. (3) Assess for trauma symptoms and treat with standard trauma-focused care. (4) Inform them of reporting options (police, health regulators, consumer bodies) and let them decide, unless a mandatory reporting duty applies (for example, a child at risk). (5) Separate the drug experience from what was done to them. [synthesis]
Example language (illustrative): "What happened to you there wasn't your fault, whatever the substance did. We can look at both parts separately."
Watch for: self-blame, mistrust of all helpers. Working: safety, reduced symptoms, informed choice about reporting.

5. Handling problems

The trial sources describe no protocol for challenging experiences (GH001 kept Challenging Experience Questionnaire results for a later paper) and no psychotherapy. Nearly all guidance below is therefore [synthesis], with source tags where a fact comes from the literature. [source: Reckweg et al. 2023]

Acute fear or panic during a trial session. Keep calm, brief orienting statements ("You're safe; it will pass soon"); don't interpret; let the physician lead on anything physical. Anxiety was among the most common adverse events in trials and resolved on its own. [source: Reckweg et al. 2021; 2023; synthesis]
Client distressed by the experience afterwards ("I thought I was dying"). Validate it, normalise that loss-of-self experiences are commonly reported, and use B5 and B6 at the client's pace. Use grounding if the person becomes overwhelmed while talking, and stop the narrative work until they are stable. [synthesis]
Distressing reactivations. Use B7. Refer for medical and neurological assessment if episodes are frequent or include altered awareness, unusual movements or confusion. [source: Ortiz Bernal et al. 2022; Dourron et al. 2023; uncertain]
Emergent mania, psychosis or suicidality. Treat as an emergency under your usual risk procedures; with a trial participant, inform the trial team at once. These conditions were exclusions because of their risk. [source: Reckweg et al. 2023; synthesis]
No benefit in a trial, or relapse after initial response. Validate the disappointment; screen for suicide risk, as hope may have been invested in it; restart or adjust evidence-based treatment with the prescriber; check whether the trial offers further follow-up. [synthesis] Note that published response figures are short-term and from selected samples. [source: Reckweg et al. 2023; atai 2025]
Excluded from a trial. Explain that exclusion protects them; explore their reaction; discourage turning to unregulated providers instead; keep standard treatment going. [synthesis]
Client wants you to attend, recommend, vet or run a session. Decline clearly and explain why (legal, ethical and competence limits). Offer B1 to B3 and integration instead. [synthesis]
Client hides use or plans after feeling judged (non-adherence to honesty). Name the stance explicitly: you won't punish disclosure; your aim is their safety. Repair the alliance before giving more information. [synthesis]
Rupture over disagreement about use. Acknowledge the client's autonomy and your duty to state concerns; use standard rupture repair (name it, take your share, ask what they need). Do not trade your safety advice for alliance. [synthesis]
Client stops medication on their own to use it. See B4; involve the prescriber, monitor withdrawal and relapse, and assess risk. [synthesis]
Seeking repeat use to recapture the experience. Craving was reported by about 8% of survey respondents; explore what the repetition is for; work with the underlying need; assess substance-use patterns overall, as polysubstance use was common in the survey sample. [source: Davis et al. 2018; synthesis]
Spiritual bypassing or major life decisions based on the experience. Agree a waiting period for irreversible decisions; explore the decision's other drivers; if a faith community matters to the client, invite them to involve it. [synthesis]
Group or retreat context with pressure or abuse. Use B10; assess for coercion and trauma; explain reporting options; meet mandatory reporting duties. [synthesis] [uncertain: no documented cases in the sources]
Cultural or ceremonial framing. If a client describes Indigenous or religious ceremony, do not judge or describe the ceremony; ask what the community's own guidance and aftercare are; refer back to the people who hold that authority if the client wishes; work with the personal meaning. [synthesis]
Your own competence and legal exposure. Check local law and your licensing body's guidance before discussing harm reduction; document the advice; get supervision or consultation from colleagues trained in psychedelic integration. [synthesis]

Sources

Pages actually opened (titles abbreviated where the full title names a route of administration):

Further reading (not drawn on): Ermakova AO, et al. (2022). A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology. [uncertain] The GH001 phase 2b full paper (JAMA Psychiatry, 2025) is not drawn on here; its results are cited from the company release only. [uncertain]

Notes on gaps: no source opened describes staffing roles, music, touch policy or a challenging-experience protocol for 5-MeO-DMT sessions, and neither industry programme published a psychotherapy component. Interventions A5 and B1 to B10 are clinical synthesis built around the published frame.

← Previous · VII-061Ibogaine treatment for addiction Next · VII-063 →LSD and psilocybin for alcohol use disorder